Convalescent plasma study also showing mortality based on HCQ treatment, unadjusted hazard ratio uHR 1.37, p
= 0.28. Confounding by indication is likely.
Salazar et al., 11/4/2020, retrospective, USA, North America, peer-reviewed, 19 authors.
risk of death, 37.0% higher, RR 1.37, p = 0.28, treatment 12 of 92 (13.0%), control 80 of 811 (9.9%).
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely, unadjusted results with no group details.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.